Direct-acting antivirals (DAAs) are known to present with additional dermatological events over pegylated-interferon/ribavirin (Peg-IFN/RBV).
Objective:
A systematic review and meta-analysis was conducted to assess the incidence/risk of cutaneous adverse events (AEs) for simeprevir, sofosbuvir, ABT450/r-ombitasvir, dasabuvir, ledipasvir, daclatasvir, and asunaprevir.
Methods:
The databases searched included PubMed, Clinicaltrials.gov, and Clinicaloptions.com. Data on telaprevir and boceprevir were obtained from a previous study.
Results:
The incidences of cutaneous AEs were 34.3% (95% CI 18.4%-54.8%) for the old DAAs + Peg-IFN/RBV, 22.0% (95% CI 17.9%-26.8%) for the new DAAs + Peg-IFN/RBV, 9.8% (95% CI 8.6%-11.2%) for the DAAs + RBV, and 3.8% (95% CI 2.4%-6.1%) for DAAs only. Simeprevir + Peg-IFN/RBV was associated with an increased relative risk over Peg-IFN/RBV; RR = 1.319 (95% CI 1.026-1.697).
Conclusion:
Dermatological events are still an important issue for many of the new DAAs. Appropriate monitoring, management, and patient education are needed to minimize AEs and achieve HCV cure.
NainanOVAlterMJKruszon-MoranD. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006;131(2):478-484.
4.
SimmondsPBukhJCombetC. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-973.
5.
ParkCJiangSLawsonKA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014;39(1):14-24.
BiesbroeckLKScottJDTaraskaCMooreEFalseyRRShinoharaMM. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment. Am J Clin Dermatol. 2013;14(6):497-502.
9.
KumadaHToyotaJOkanoueTChayamaKTsubouchiHHayashiN. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78-84.
10.
JacobsonIMMcHutchisonJGDusheikoG. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
11.
HezodeCForestierNDusheikoG. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.
12.
McHutchisonJGEversonGTGordonSC. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
13.
ZeuzemSAndreonePPolS. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
14.
McHutchisonJGMannsMPMuirAJ. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292-1303.
15.
PoordadFMcConeJJrBaconBR. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
16.
KwoPYLawitzEJMcConeJ. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705-716.
17.
BaconBRGordonSCLawitzE. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
18.
FlammSLLawitzEJacobsonI. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013;11(1):81-87 e84; quiz e85.
19.
SamainADuval-ModesteABJolyP. First case of drug rash eosinophilia and systemic symptoms due to boceprevir. J Hepatol. 2014;60(4):891-893.
20.
US Department of Health and Human Services, ed. Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Revision 1. Fed Reg. 2013.
21.
PawlotskyJM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176-1192.
17th Annual Meeting of UK and Ireland-based Contributors to The Cochrane Collaboration—University of Loughborough, UK. Paper presented at: Cochrane Collaboration UK Contributors’ Meeting; March2012; Loughborough, UK.
29.
US Department of Health and Human Services, ed. Advisory Committee briefing document for NDA 201-917 Telaprevir 375 mg tablets. 2011.
30.
JacobsonIMDoreGJFosterGR. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403-413.
31.
MannsMMarcellinPPoordadF. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414-426.
32.
FornsXLawitzEZeuzemS. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669-1679e1663.
33.
LawitzEMangiaAWylesD. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887.
34.
LawitzELalezariJPHassaneinT. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-408.
35.
KowdleyKVLawitzECrespoI. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-2107.
36.
GaneEJStedmanCAHylandRH. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
37.
LalezariJP NDHylandRH, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. Paper presented at: European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, Netherlands.
38.
JacobsonIMGordonSCKowdleyKV. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
39.
AfdhalNZeuzemSKwoP. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
40.
AfdhalNReddyKRNelsonDR. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
41.
KowdleyKVGordonSCReddyKR. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
42.
LawitzEPoordadFFPangPS. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-523.
43.
KohliA SZMartiM. Combination oral, hepatitis C antiviral therapy for 6 or 12 weeks: results of the SYNERGY trial. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
44.
GaneEJStedmanCAHylandRH. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736-743e731.
45.
GaneEJHRAn D. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Paper presented at: European Association for the Study of the Liver; April 9-13, 2014; London, UK.
46.
AndreonePColomboMGEnejosaJV. ABT-450, Ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365e351.
47.
PoordadFHezodeCTrinhR. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982.
48.
FeldJJKowdleyKVCoakleyE. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-1603.
49.
FerenciPBernsteinDLalezariJ. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
50.
ZeuzemSJacobsonIMBaykalT. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
MinkisKGardenBCWuSPulitzerMPLacoutureME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121-e128.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
